On September 9, 2024, Brett Sandercock, Chief Financial Officer of ResMed Inc (RMD, Financial), sold 1,000 shares of the company at a price of $246.42 per share. The transaction was documented in a recent SEC Filing. Following this sale, the insider now owns 96,812 shares of ResMed Inc.
ResMed Inc is a global leader in the development, manufacturing, and marketing of medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders, including sleep apnea, chronic obstructive pulmonary disease, and other chronic diseases.
Over the past year, Brett Sandercock has engaged in multiple transactions involving the company's stock. The insider has sold a total of 20,000 shares and has not made any purchases of the stock during this period. This recent sale is part of a broader trend observed within the company, where there have been 26 insider sells and no insider buys over the past year.
On the valuation front, ResMed Inc's shares were trading at $246.42 on the day of the sale, giving the company a market cap of approximately $37.15 billion. The price-earnings ratio of the company stands at 36.49, which is above the industry median of 26.32. Despite this, the stock is considered to be Fairly Valued with a price-to-GF Value ratio of 0.9, based on a GF Value of $275.13.
The GF Value is a proprietary measure used to determine the fair value of a stock, taking into account historical trading multiples, adjustments based on the company's past performance, and future business expectations.
This insider sale might interest investors tracking insider behaviors as an indicator of the company’s performance and stock valuation perspectives.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
